Literature DB >> 1721372

Adverse effects associated with the use of FK 506.

J J Fung1, M Alessiani, K Abu-Elmagd, S Todo, R Shapiro, A Tzakis, D Van Thiel, J Armitage, A Jain, J McCauley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721372      PMCID： PMC2952509     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  13 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Early trials with FK 506 as primary treatment in liver transplantation.

Authors:  S Todo; J J Fung; A J Demetris; A Jain; R Venkataramanan; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

Review 4.  The diagnosis and treatment of posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; L Makowka; T E Starzl
Journal:  Curr Probl Surg       Date:  1988-06       Impact factor: 1.909

5.  Liver transplantation with use of cyclosporin a and prednisone.

Authors:  T E Starzl; G B Klintmalm; K A Porter; S Iwatsuki; G P Schröter
Journal:  N Engl J Med       Date:  1981-07-30       Impact factor: 91.245

6.  A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.

Authors:  M W Harding; A Galat; D E Uehling; S L Schreiber
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

7.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

8.  Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

Review 9.  Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring.

Authors: 
Journal:  Clin Chem       Date:  1987-07       Impact factor: 8.327

10.  Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors:  S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982
View more
  33 in total

1.  Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide.

Authors:  C Rastellini; L Cicalese; R Leach; M Braun; J J Fung; T E Starzl; A S Rao
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

Review 2.  Advances in the development of immunosuppressive agents in organ transplantation.

Authors:  T Ochiai; K Isono
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

3.  Hyponatremia during administration of tacrolimus in an allogeneic bone marrow transplant recipient.

Authors:  Taichi Azuma; Hiroshi Narumi; Kensuke Kojima; Yuichiro Nawa; Masamichi Hara
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 4.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

Review 5.  FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors:  A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal:  Springer Semin Immunopathol       Date:  1993

6.  Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression.

Authors:  O Odocha; J McCauley; V Scantlebury; R Shapiro; P Carroll; M Jordan; C Vivas; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-08       Impact factor: 1.066

7.  Long-term insulin requirement after liver transplantation with FK 506 in American veterans.

Authors:  J Tabasco-Minguillan; L Mieles; P Carroll; J Gavaler; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

8.  Adverse effects of FK 506 overdosage after liver transplantation.

Authors:  M Alessiani; U Cillo; J J Fung; W Irish; K Abu-Elmagd; A Jain; S Takaya; D Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

9.  Interferon-associated left ventricular dysfunction in a liver transplant recipient.

Authors:  R Mateo; S Jethmalani; D C Angus; J Gorcsan; B Uretsky; J Fung
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

10.  Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506).

Authors:  K Abu-Elmagd; D H Van Thiel; B V Jegasothy; J C Jacobs; P Carroll; H Rodriquez-Rilo; C D Ackerman; J J Fung; T E Starzl
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.